NURTURE: WHO motor milestones

Early SPINRAZA® treatment may allow for age-appropriate development1

  • SPINRAZA®-treated children achieved milestones unexpected in Type I or II SMA and more consistent with normal development1
  • At the interim analysis, 100% (25 of 25) patients had the ability to suck and swallow and 88% (22 of 25) had achieved a maximal score on the HINE Section 11

SPINRAZA® -treated children at interim analysis1

Scheme
Scheme

*3 patients were aged <15 months (WHO-defined window for expected age of achievement - 95th percentile).

Banner
Banner

Stock image (not a real patient).

References:
1. SPINRAZA® Summary of Product Characteristics.